TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 5c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q3 EPS of ($0.67), $0.05 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.66 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery